The most frequent treatment-related adverse event (TRAE) was hyperglycemia, an on-target toxicity associated with PI3K inhibition23, which was reported in 90.2% (n = 46) of patients at any grade (Table 2). The gene discussed is PIK3CA; the disease is Hyperglycemia.